Bump in the Road for Lyme Disease Vaccine Trials

Published on February 17, 2023

Just when we thought the road to a Lyme disease vaccine was clear, there’s been a unexpected detour. Like a hiccup during a pit stop, Pfizer Inc and Valneva are halting their late-stage study on a Lyme disease vaccine in half of the U.S. patients due to a breach of clinical trial guidelines by a third-party contractor. It’s like having to pump the brakes right when you were about to speed ahead. But fear not, scientists and researchers are always ready to tackle any obstacles that come their way! Although this setback might delay the release of a potential vaccine, it’s important to remember that it’s all part of the scientific process. Understanding what went wrong will only lead to better techniques and improved future trials. In the meantime, let’s stay optimistic and continue supporting research efforts to combat Lyme disease.

Drugmaker Pfizer Inc and France’s Valneva will stop testing a Lyme disease vaccine in roughly half of U.S. patients in a late-stage study, the companies said, citing a breach of clinical trial guidelines by a third-party contractor. The joint statement on Friday did not…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>